Maury Raycroft
Stock Analyst at Jefferies
(1.95)
# 3,194
Out of 5,240 analysts
58
Total ratings
34.78%
Success rate
-3.4%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Downgrades: Hold | $18 → $27 | $24.87 | +8.56% | 2 | May 14, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $36 → $33 | $12.03 | +174.31% | 3 | May 13, 2026 | |
| TYRA Tyra Biosciences | Maintains: Buy | $32 → $43 | $36.51 | +17.78% | 4 | Feb 3, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $66 → $81 | $85.93 | -5.74% | 3 | Feb 2, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $114 → $63 | $25.83 | +143.90% | 1 | Dec 30, 2025 | |
| MREO Mereo BioPharma Group | Downgrades: Hold | $7 → $0.5 | $0.25 | +103.25% | 2 | Dec 30, 2025 | |
| CELC Celcuity | Maintains: Buy | $108 → $134 | $134.72 | -0.53% | 2 | Dec 2, 2025 | |
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $15.84 | +32.62% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.10 | +45.45% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $293.45 | +87.08% | 4 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $38.70 | -61.24% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3.5 | $1.73 | +102.31% | 1 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $1.98 | +304.04% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $10.38 | -42.20% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $3.17 | +373.20% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $25.27 | +612.45% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.35 | +1,603.70% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $2.10 | +9,185.71% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $9.55 | +15.22% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $39.63 | -84.86% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $79.66 | -5.84% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $3.40 | +223.53% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.48 | +237.84% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $5.98 | +502.01% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $7.63 | +1,276.15% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $50.45 | +240.93% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.88 | +1,531.94% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $13.10 | +220.73% | 3 | Nov 1, 2017 |
Tango Therapeutics
May 14, 2026
Downgrades: Hold
Price Target: $18 → $27
Current: $24.87
Upside: +8.56%
Corbus Pharmaceuticals Holdings
May 13, 2026
Maintains: Buy
Price Target: $36 → $33
Current: $12.03
Upside: +174.31%
Tyra Biosciences
Feb 3, 2026
Maintains: Buy
Price Target: $32 → $43
Current: $36.51
Upside: +17.78%
Dianthus Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $66 → $81
Current: $85.93
Upside: -5.74%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Buy
Price Target: $114 → $63
Current: $25.83
Upside: +143.90%
Mereo BioPharma Group
Dec 30, 2025
Downgrades: Hold
Price Target: $7 → $0.5
Current: $0.25
Upside: +103.25%
Celcuity
Dec 2, 2025
Maintains: Buy
Price Target: $108 → $134
Current: $134.72
Upside: -0.53%
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $15.84
Upside: +32.62%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.10
Upside: +45.45%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $293.45
Upside: +87.08%
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $38.70
Upside: -61.24%
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $1.73
Upside: +102.31%
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.98
Upside: +304.04%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $10.38
Upside: -42.20%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.17
Upside: +373.20%
Mar 13, 2024
Initiates: Buy
Price Target: $180
Current: $25.27
Upside: +612.45%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.35
Upside: +1,603.70%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $2.10
Upside: +9,185.71%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $9.55
Upside: +15.22%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $39.63
Upside: -84.86%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $79.66
Upside: -5.84%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $3.40
Upside: +223.53%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.48
Upside: +237.84%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $5.98
Upside: +502.01%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $7.63
Upside: +1,276.15%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $50.45
Upside: +240.93%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.88
Upside: +1,531.94%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $13.10
Upside: +220.73%